AbbVie | ABBV - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Abbott USD 9.31B 104M 2026-03
ALKERMES USD 1.75B 1.43B 2026-03
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eisai JPY 215.74B 15.84B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
J&J USD 17.44B 1.53B 2026-03
Medtronic USD 7.72B 436M 2026-03
Merck USD 18.17B 8.01B 2026-03
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novartis USD 9.29B 507M 2026-03
Pacira USD 172.75M 20.93M 2026-03
Perrigo USD 935.6M 89.6M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
UCB EUR 2.96B 196M 2025-12
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03
Zoetis USD 3.23B 1.68B 2026-03